China Micra Transcatheter Pacing Study

Overview

The China Micra Transcatheter Pacing Study is a prospective, multi-center, single arm human clinical trial utilizing Objective Performance Criterion (OPC) to confirm the safety and efficacy profile of the Micra system for regulatory approval in China.

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: N/A
    • Intervention Model: Single Group Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)
  • Study Primary Completion Date: August 29, 2019

Detailed Description

All study sites will be in China. Subjects successfully implanted with the Micra system in all sites will be followed at implant/pre-discharge, 1-month, 3-months, and 6-months, and at 6-month intervals thereafter (if applicable) through study closure. The overall follow-up period of the study will end when the last enrolled patient has 6 months of follow-up.

Interventions

  • Device: Micra Transcatheter Pacing System (TPS)
    • Treatment of subjects eligible for the single chamber ventricular pacemaker per study requirements

Arms, Groups and Cohorts

  • Experimental: Micra Implant Group
    • Subjects with implant attempt with the Micra Transcatheter Pacing System (TPS)

Clinical Trial Outcome Measures

Primary Measures

  • Percentage of Participants With Major Complications Free Survival Probability
    • Time Frame: 6 months post implant
    • Freedom rate from Micra implant procedure and/or system related major complications through 6 months post implant

Secondary Measures

  • Pacing Capture Threshold (PCT)
    • Time Frame: Implant, Discharge, Month 1, Month 3, Month 6
    • Pacing capture threshold @0.24ms pulse width Capture threshold is defined as the minimum electrical stimulus required to consistently capture the heart outside of the myocardial refractory period. Pulse width is the duration of the current flow expressed in milliseconds. The pulse width must be long enough for depolarization to disperse to the surrounding tissue.
  • Impedance
    • Time Frame: Implant, Discharge, Month 1, Month 3, Month 6
    • Impedance measured from the Micra device Impedance is the opposition to current flow.
  • Sensing Amplitude
    • Time Frame: Implant, Discharge, Month 1, Month 3, Month 6
    • R-wave sensing amplitude measured from the Micra device Sensing is the ability of the pacemaker to “see” when a natural (intrinsic) depolarization is occurring.
  • Adverse Device Effect
    • Time Frame: From implant attempt to last subject follow-up, ranging from 0 to 14 months
    • Adverse event related to the Micra system or implant procedure

Participating in This Clinical Trial

Inclusion Criteria

1. Subjects who have a Class I or II indication for implantation of a single chamber ventricular pacemaker according to ACC/AHA/HRS 2008 guidelines and China guideline. 2. Subjects who are willing to participate in study through consent and willing to undergo study specific required procedures with expectancy of geographically stable for follow up duration. 3. Subjects who are at least 18 years of age. Exclusion Criteria:

1. Subject has an existing or prior pacemaker, ICD or CRT device implant. 2. Subject has unstable angina pectoris or has had an acute myocardial infarction (AMI) in the 30 days prior to eligibility assessment. 3. Subjects with current implantation of neurostimulator or any other chronically implanted device which uses current in the body. Note that a temporary pacing wire is allowed. 4. Subjects with a mechanical tricuspid valve, implanted vena cava filter, or left ventricular assist device (LVAD). 5. Subjects who are morbidly obese and physician believes telemetry communication of ≤5 inches (12.5 cm) could not be obtained with programmer head. 6. Subjects whose femoral venous anatomy is unable to accommodate a 23 French introducer sheath or implant on the right side of the heart (for example, due to obstructions or severe tortuosity) in the opinion of the implanter. 7. Subjects who are considered as unable to tolerate an urgent sternotomy. 8. Subjects with a known intolerance to Nickel-Titanium (Nitinol) Alloy. 9. Subjects for whom a single dose of 1.0mg dexamethasone acetate may be contraindicated. 10. Subjects with a life expectancy of less than 12-months. 11. Subjects who are currently enrolled or planning to participate in a potentially confounding drug or device trial during the course of this study. Co-enrollment in concurrent trials is only allowed when document pre-approval is obtained from the Medtronic study manager. 12. Pregnant women or breastfeeding women, or women of child bearing potential and who are not on a reliable form of birth regulation method or abstinence. 13. Subjects with exclusion criteria required by local law (age or other). 14. Subjects with medical condition which precludes patient from participation in the opinion of the Investigator.

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Medtronic Cardiac Rhythm and Heart Failure
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Shu Zhang, MD, Principal Investigator, Chinese Academy of Medical Sciences, Fuwai Hospital

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.